X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 45 filers reported holding X4 PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $517,416 | -44.2% | 474,693 | -0.7% | 0.00% | – |
| Q2 2023 | $927,764 | +522.9% | 478,229 | +179.4% | 0.00% | – |
| Q1 2023 | $148,938 | -12.4% | 171,193 | 0.0% | 0.00% | – |
| Q4 2022 | $169,995 | -28.9% | 171,193 | +22.5% | 0.00% | – |
| Q3 2022 | $239,000 | +77.0% | 139,696 | 0.0% | 0.00% | – |
| Q2 2022 | $135,000 | -45.1% | 139,696 | -0.7% | 0.00% | – |
| Q1 2022 | $246,000 | -47.4% | 140,612 | +158.6% | 0.00% | – |
| Q1 2021 | $468,000 | +39.3% | 54,365 | +3.9% | 0.00% | – |
| Q4 2020 | $336,000 | +0.9% | 52,300 | +6.4% | 0.00% | – |
| Q3 2020 | $333,000 | -25.5% | 49,153 | +2.6% | 0.00% | – |
| Q2 2020 | $447,000 | +14.9% | 47,901 | +23.0% | 0.00% | – |
| Q1 2020 | $389,000 | +11.1% | 38,932 | +19.0% | 0.00% | – |
| Q4 2019 | $350,000 | +1.7% | 32,713 | +20.9% | 0.00% | – |
| Q3 2019 | $344,000 | +63.8% | 27,065 | +93.5% | 0.00% | – |
| Q2 2019 | $210,000 | – | 13,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |